CD133 was significantly associated with high-grade serous carcinoma, late-stage disease, ascites severity and resistance to therapy when evaluated through Tissue Microarray in 400 ovarian carcinoma samples38. The gene discussed is PROM1; the disease is serous adenocarcinoma.